Dengue is an epidemic disease caused by mosquitoes and is prevalent throughout tropical and subtropical region across the world. The Dengue virus or DENV is the most prevalent mosquito borne viral pathogen in human. An initial infection with one of the four distinct dengue virus serotypes is mild., while, an infection with a second serotype often cause severe symptoms which include internal bleeding, joint and muscle aches and a debilitating fever. Because there is no such drug for dengue, every year an estimated 20,000 people die and nearly 500,000 require hospitalization.

Experts believed that to get rid of complications from the second infection, a vaccine must be discovered that can provide protective effect against all four serotypes (DENV-1, -2, -3, -4).

About Sanofi Pasteur’s dengue vaccine and clinical program

As India is suffering from increased number of dengue fever, Sanofi, a Parma major announced the availability of world’s first vaccine against mosquito borne viral disease to be available by second half of 2015. This tetravalent vaccine for dengue is enduring phase III trials in Australia. This indicates that the other two trials of this vaccine has shown capability of producing an immune response and is now in confirming those results by demonstrating protection against disease and monitoring the side effects against the larger group.

The phase III potency clinical study program for the vaccine was conducted over 31,000 participants across 10 contagious countries in Asia and America. Results of the last stage showed that the vaccine gives 95.5% effective protection against severe dengue and about 80.3% reduction in the risk of hospitalization.

About 20,000 Latin American children aged between 9 – 16 years were listed in the trial. Of those children, 12,574 were provided with 3 doses of vaccine over the course of 12 months, while the rest of the children received an inactive drug. Results of the trial indicate that the vaccine was 60.8% effective against dengue and hence, reduced the risk of getting hospitalized for dengue by 80.3% during the 25 months surveillance period study.

About Sanofi

Sanofi is a global healthcare leader who discovers, develops and distributes remedial significance depending upon the patient’s needs. It has growth backbone in the field of healthcare with seven growth platforms: human vaccines, diabetes solutions, consumer healthcare, innovative drugs, animal health and new Genzymes.

About Sanofi Pasteur

Sanofi Pasteur is a vaccine section of Sanofi and dispense more than one billion doses of vaccine each year. A world leader in the vaccine industry, it offers the wide range of vaccines defending against 20 infectious diseases.

disclaimer icon All images and content mentioned herewith have been shared by the authors/contributors. We do not hold any liability for infringement or breach of copyright of third parties across the spectrum. Pictures shared by authors/contributors are deemed to be authorized by them likewise. For any disputes, we shall not be held responsible.